Kelun-Biotech’s TROP2 ADC Shows Strong Results in TNBC and NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company")  announced that results from a Phase 3 registrational clinical study evaluating...

April 14, 2025 | Monday | News
Amgen’s IMDELLTRA® Shows Survival Benefit in Phase 3 Trial for Small Cell Lung Cancer

Amgen, announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with ...

April 14, 2025 | Monday | News
Cellistic Introduces Echo™-NK Platform to Power Scalable Off-the-Shelf NK Cell Therapies for Cancer and Autoimmune Diseases

Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manuf...

April 11, 2025 | Friday | News
AbbVie’s RINVOQ® Becomes First Oral JAK Inhibitor Approved in EU for Giant Cell Arteritis

AbbVie announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment ...

April 10, 2025 | Thursday | News
Gift of Life Biologics and Cellex Cell Professionals Celebrate Ongoing Success of Collaborative Partnership in Cell and Gene Therapy

Gift of Life Biologics, a leading supplier of high-quality cellular starting materials in the US, and Cellex Cell Professionals, a trusted Contract De...

April 08, 2025 | Tuesday | News
Halozyme’s ENHANZE® Technology Powers European Approval of Subcutaneous RYBREVANT® for Advanced NSCLC Treatment

 Halozyme Therapeutics, Inc.announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) mark...

April 08, 2025 | Tuesday | News
ABL Bio and GSK Forge Licensing Agreement to Develop Innovative Neurodegenerative Disease Treatments Using BBB Shuttle Platform

ABL Bio Inc. a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a wor...

April 07, 2025 | Monday | News
AstraZeneca’s Imfinzi (Durvalumab) Gains European Union Approval for Resectable Non-Small Cell Lung Cancer Treatment

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adult...

April 07, 2025 | Monday | News
AVITA Medical Launches Cohealyx™ in the U.S., Expanding Portfolio for Transformative Acute Wound Care

AVITA Medical, Inc., a leading therapeutic acute wound care company delivering transformative solutions, announced the U.S. commercial launch of Cohealyx&t...

April 07, 2025 | Monday | News
Mesoblast Confirms U.S. Tariff Exemption for Allogeneic Cellular Products, Including Ryoncil® and Revascor®

Mesoblast, global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on the status of its products in relation to the U....

April 04, 2025 | Friday | News
Thermo Fisher Scientific Launches Krios 5 Cryo-TEM Revolutionizing Structural Biology with Enhanced Throughput and AI Automation

Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Krios™ 5 Cryo-TEM. This next-generati...

April 03, 2025 | Thursday | News
Genentech Reports Phase III MUSETTE Trial Results for Ocrevus® Showing No Additional Benefit from Higher Dose in Relapsing MS

Genentech, a member of the Roche Group, announced  that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intraveno...

April 03, 2025 | Thursday | News
Roche Reports Phase III MUSETTE Trial Results Showing No Additional Benefit from Higher Dose of OCREVUS® in Relapsing MS

Roche announced that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OC...

April 03, 2025 | Thursday | News
Yingli Pharma Receives FDA Clearance to Launch Phase 3 Trial for Linperlisib in Relapsed/Refractory PTCL

Shanghai Yingli Pharmaceutical Co., Ltd., a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune dis...

April 02, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close